Unió Europea -
hongarès -
EMA (European Medicines Agency)
carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - myeloma multiplex - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
Hongria -
hongarès -
NÉBIH (Nemzeti Élelmiszerlánc-biztonsági Hivatal)
syncroprost, 0,250 mg/ml oldatos injekció szarvasmarhák, lovak, sertések és kecskék számára a.u.v.
ceva-phylaxia oltóanyagtermelo zrt. - kloprosztenol-nátrium - oldatos injekció - cloprostenol - szarvasmarha, kecske, sertés, ló
Unió Europea -
hongarès -
EMA (European Medicines Agency)
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - myeloma multiplex - daganatellenes szerek - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
Unió Europea -
hongarès -
EMA (European Medicines Agency)
tecvayli
janssen-cilag international n.v. - teclistamab - myeloma multiplex - daganatellenes szerek - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
Hongria -
hongarès -
OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)
thiotepa medac 15 mg por oldatos infúzióhoz való koncentrátumhoz
medac gmbh - thiotepa -
Hongria -
hongarès -
OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)
thiotepa medac 100 mg por oldatos infúzióhoz való koncentrátumhoz
medac gmbh - thiotepa -
Unió Europea -
hongarès -
EMA (European Medicines Agency)
columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - daganatellenes szerek - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.
Unió Europea -
hongarès -
EMA (European Medicines Agency)
talvey
janssen-cilag international n.v. - talquetamab - myeloma multiplex - daganatellenes szerek - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
Unió Europea -
hongarès -
EMA (European Medicines Agency)
tepkinly
abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - daganatellenes szerek - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.